National Institute on Drug Abuse; Notice of Closed Meetings, 8691 [2024-02526]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 27 / Thursday, February 8, 2024 / Notices
Dated: February 2, 2024.
Lauren Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2024–02526 Filed 2–7–24; 8:45 am]
National Institute on Drug Abuse;
Notice of Closed Meetings
BILLING CODE 4140–01–P
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; FieldDeployable, Low-Cost Point-of-Need
Approaches and Technologies to Lower the
Barriers to Substance Use Disorders (SUD)
Diagnosis and Treatment.
Date: March 6, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, caitlin.moyer@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA L
Conflict SEP.
Date: March 15, 2024.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Contact Person: Sudhirkumar Udhavrao
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, sudhirkumar.yanpallewar@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
VerDate Sep<11>2014
17:34 Feb 07, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Council of Research Advocates.
The meeting will be a hybrid meeting
held in-person and virtually and will be
open to the public as indicated below,
with attendance limited to space
available. Individuals who plan to
attend in-person or view the virtual
meeting and need special assistance or
other reasonable accommodations,
should notify the Contact Person listed
below in advance of the meeting. The
meeting can be accessed from the NIH
Videocast at the following link: https://
videocast.nih.gov.
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: March 5, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: Welcome and Chairwoman’s
Remarks, NCI Director’s Update, NCI
Updates, and Legislative Update.
Place: Porter Neuroscience Research
Center, National Institutes of Health,
Building 35A, Room 610, 35 Convent Drive,
Bethesda, MD 20892–2580 (Hybrid Meeting).
Contact Person: Amy Williams, Acting
Director, NCI Office of Advocacy Relations,
National Cancer Institute, NIH, 31 Center
Drive, Building 31, Room 10A28, Bethesda,
MD 20892, (240) 781–3406, williaam@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: NCRA: https://
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
8691
deainfo.nci.nih.gov/advisory/ncra/ncra.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 5, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02592 Filed 2–7–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health
and Human Development Special Emphasis
Panel; HEAL Initiative: Limited Competition:
Clinical Outcomes of Babies with Opioid
Exposure (OBOE) Study (UG1).
Date: March 25, 2024.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, 6710B
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Kimberly L. Houston,
M.D., Scientific Review Branch, Eunice
Kennedy Shriver National Institute of Child
Health & Human Development, NIH, 6710B
Rockledge Drive, Rm. 2137C, Bethesda, MD
20892, (301) 827–4902, kimberly.houston@
nih.gov.
E:\FR\FM\08FEN1.SGM
08FEN1
]]>Agencies
[Federal Register Volume 89, Number 27 (Thursday, February 8, 2024)]
[Notices]
[Page 8691]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02526]
[[Page 8691]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Field-Deployable, Low-Cost Point-of-Need Approaches
and Technologies to Lower the Barriers to Substance Use Disorders
(SUD) Diagnosis and Treatment.
Date: March 6, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Contact Person: Caitlin Elizabeth Angela Moyer, Ph.D.,
Scientific Review Officer, Scientific Review Branch, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443-4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA L Conflict SEP.
Date: March 15, 2024.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Contact Person: Sudhirkumar Udhavrao Yanpallewar, M.D.,
Scientific Review Officer, Scientific Review Branch, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443-4577,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 2, 2024.
Lauren Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02526 Filed 2-7-24; 8:45 am]
BILLING CODE 4140-01-P
